Short answer
Bausch Health Companies Inc (BHC) filed an 8-K current report with the SEC on July 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Press release announces Bausch Health’s results for quarter ended June 30, 2026.
Bausch Health Companies Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Bausch Health’s results for quarter ended June 30, 2026
- Exhibit 99.1 contains operating results and other financial information for the quarter
- Investors should review Exhibit 99.1 for revenue, profitability, cash flow and guidance details
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $2.85B, up 13% reported and 11% organic, indicating broad-based operating momentum
- GAAP EPS $0.68 versus $0.40, while adjusted EPS rose 40% to $1.26
- Adjusted EBITDA $1.075B, up 28%, with operating cash flow surging 132% to $671M
- Salix revenue grew 21% organically, led by Xifaxan growth of 26%; Bausch + Lomb grew 8% organically
- 2026 guidance raised: revenue $10.790B-$11.040B, adjusted EBITDA $4.050B-$4.175B, adjusted operating cash flow $1.400B-$1.475B
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bausch Health Companies Inc 8-K filings
Get the next BHC 8-K as it lands
Follow BHC for push alerts, or ask the research agent what this filing means.